Boyd Watterson Asset Management LLC OH Sells 20,052 Shares of Pfizer Inc. (NYSE:PFE)

Boyd Watterson Asset Management LLC OH reduced its stake in Pfizer Inc. (NYSE:PFE) by 33.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 40,796 shares of the biopharmaceutical company’s stock after selling 20,052 shares during the quarter. Boyd Watterson Asset Management LLC OH’s holdings in Pfizer were worth $1,175,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in PFE. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Pfizer by 30.9% during the third quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock valued at $797,901,000 after purchasing an additional 5,678,004 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Pfizer by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after purchasing an additional 5,185,453 shares in the last quarter. Bank of Nova Scotia boosted its stake in shares of Pfizer by 219.4% during the third quarter. Bank of Nova Scotia now owns 5,503,983 shares of the biopharmaceutical company’s stock valued at $182,567,000 after purchasing an additional 3,780,696 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Pfizer by 38.9% during the third quarter. Canada Pension Plan Investment Board now owns 10,028,940 shares of the biopharmaceutical company’s stock valued at $332,660,000 after purchasing an additional 2,807,846 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PFE shares. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.14 during midday trading on Friday, reaching $25.40. The company’s stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The firm has a market capitalization of $143.83 billion, a PE ratio of 70.50, a P/E/G ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The stock has a fifty day moving average of $26.96 and a 200 day moving average of $28.42. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.61%. Pfizer’s dividend payout ratio is presently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.